2017 American Transplant Congress
Kidney Allocation Using CMV Matching Optimizes Low and High Risk Profiles for Prevention of CMV Infection in Kidney Transplant Recipients.
Cytomegalovirus (CMV) confers a major impact on morbidity, mortality, and graft survival in kidney transplant recipients. Efforts to prevent CMV disease and infection have traditionally…2017 American Transplant Congress
Impact of Everolimus Added to a De Novo Belatacept Regimen on the Risk of BK Viremia After Kidney Transplant.
IntroductionBK viremia is a common complication following kidney transplantation. In vitro data suggest that inhibition of the mTOR–SP6-kinase pathway prevents expression of early viral genes…2017 American Transplant Congress
Utility of “High-Dose” Ganciclovir in High Viral Load CMV Infection in Transplant Recipients.
Background: High-dose ganciclovir (GCV) is often used for treatment of high viral load CMV, but few data exist on virologic outcomes and risk of neutropenia.…2017 American Transplant Congress
Impact of Timeliness of Assessment of Positive Cytomegalovirus Polymerase Chain Reaction Results in Abdominal Organ Transplant Recipients.
Emory University Hospital, Atlanta, GA
Purpose: The purpose of this study was to evaluate the timeliness of assessment of positive cytomegalovirus (CMV) polymerase chain reaction (PCR) results. This study served…2017 American Transplant Congress
EXPANDER-1: Exploring Renal Transplants Using Hepatitis-C Infected Donors for HCV-Negative Recipients.
Kidneys from hepatitis C-infected (HCV+) donors are underutilized in an era of severe organ shortage. In an effort to expand the donor pool, we evaluated…2017 American Transplant Congress
Reproducibility of the Cobas CMV Test (cobas CMV) and Clinical Concordance with the Cobas Ampliprep / Cobas TaqMan CMV Test (CAP/CTM CMV).
cobas CMV is a new, automated, high-throughput assay for use on the cobas 6800/8800 systems that quantifies CMV DNA in EDTA-plasma. It can be run…2017 American Transplant Congress
Contribution of New Generation Sequencing to CMV Resistance Analysis in Renal Transplant Recipients (on Behalf of the CMV Resist Group).
Results from the French Cohorts 2006-2010 and OrphaVic (NCTNCT02067169) indicates that fifty percent of graft failures in renal recipients infected by HCMV after treatment with…2017 American Transplant Congress
Usefulness of Valacyclovir Prophylaxis for Preventing Cytomegalovirus Infection After Anti-Thymocyte Globulin Treatment as Antirejection Therapy.
Anti-thymocyte globulin (ATG) treatment for acute T-cell mediated rejection (TCMR) can increase the risk of CMV infection. We purposed to evaluate the effect of valacyclovir…2017 American Transplant Congress
Can Viral Load Be Used as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Metaanalysis.
Background: Regulatory trials assessing CMV drugs have utilized symptomatic CMV disease as the primary endpoint. However CMV disease occurs infrequently, CMV syndrome is nonspecific, and…2017 American Transplant Congress
Generation of Autologous CMV and EBV-Specific T-Cell Lines from Seronegative Patients for Cell Therapy of Opportunistic Infections Following Kidney Transplantation.
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) reactivations after kidney transplant are associated with substantial morbidity, especially in seronegative patients. Adoptive immunotherapy using virus-specific T cells…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 14
- Next Page »